Literature DB >> 20102360

Angiotensin-II type 1 receptor (AT1R) and alpha-1D adrenoceptor form a heterodimer during pregnancy-induced hypertension.

M de Lourdes González-Hernández1, D Godínez-Hernández, R A Bobadilla-Lugo, P López-Sánchez.   

Abstract

Pregnancy courses with low response to angiotensin II and adrenergic agonists. In preeclampsia, both effects are reverted. It is known that angiotensin II regulates adrenergic system. It is not known, however, the interaction between both systems receptors. Our aim was to study if AT(1)R and alpha1D adrenoceptor heterodimerize in preeclampsia. We used subrenal aorctic coarctation in pregnant rats. Aortic tissues were prepared for confocal imaging and coimmunoprecipitated for alpha1D and AT(1) receptors. We found that AT(1)R and alpha1D adrenoceptor heterodimerize in both, healthy and preeclamptic groups. In healthy pregnant rats, heterodimer is barely detected. In preeclamptic rats however, we found higher heterodimerization. These results suggest that AT(1)R and alpha1D -adrenoceptor may form heterodimers, and may play a role in preeclampsia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20102360     DOI: 10.1111/j.1474-8673.2009.00446.x

Source DB:  PubMed          Journal:  Auton Autacoid Pharmacol        ISSN: 1474-8665


  9 in total

1.  Dopamine D₁-like receptors regulate the α₁A-adrenergic receptor in human renal proximal tubule cells and D₁-like dopamine receptor knockout mice.

Authors:  Riley Charles Ennis; Laureano D Asico; Ines Armando; Jian Yang; Jun B Feranil; Julie A Jurgens; Crisanto S Escano; Peiying Yu; Xiaoyan Wang; David R Sibley; Pedro A Jose; Van Anthony M Villar
Journal:  Am J Physiol Renal Physiol       Date:  2014-10-22

Review 2.  AT1 receptor signaling pathways in the cardiovascular system.

Authors:  Tatsuo Kawai; Steven J Forrester; Shannon O'Brien; Ariele Baggett; Victor Rizzo; Satoru Eguchi
Journal:  Pharmacol Res       Date:  2017-05-17       Impact factor: 7.658

Review 3.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 4.  Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism.

Authors:  Takanobu Takezako; Hamiyet Unal; Sadashiva S Karnik; Koichi Node
Journal:  Pharmacol Res       Date:  2017-06-23       Impact factor: 7.658

5.  G-protein-coupled heteromers: regulation in disease.

Authors:  Ivone Gomes; Achla Gupta; Lakshmi A Devi
Journal:  Methods Enzymol       Date:  2013       Impact factor: 1.600

6.  Functional interaction between angiotensin II receptor type 1 and chemokine (C-C motif) receptor 2 with implications for chronic kidney disease.

Authors:  Mohammed Akli Ayoub; Yuan Zhang; Robyn S Kelly; Heng B See; Elizabeth K M Johnstone; Elizabeth A McCall; James H Williams; Darren J Kelly; Kevin D G Pfleger
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

7.  Functional enhancement of AT1R potency in the presence of the TPαR is revealed by a comprehensive 7TM receptor co-expression screen.

Authors:  Jonas Tind Hansen; Christina Lyngsø; Tobias Speerschneider; Pernille B L Hansen; Céline Galés; David M Weiner; Søren P Sheikh; Ethan S Burstein; Jakob Lerche Hansen
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

8.  Angiotensin AT1 and AT2 receptor heteromer expression in the hemilesioned rat model of Parkinson's disease that increases with levodopa-induced dyskinesia.

Authors:  Rafael Rivas-Santisteban; Ana I Rodriguez-Perez; Ana Muñoz; Irene Reyes-Resina; José Luis Labandeira-García; Gemma Navarro; Rafael Franco
Journal:  J Neuroinflammation       Date:  2020-08-17       Impact factor: 8.322

Review 9.  Neurocardiac regulation: from cardiac mechanisms to novel therapeutic approaches.

Authors:  E N Bardsley; D J Paterson
Journal:  J Physiol       Date:  2018-11-12       Impact factor: 5.182

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.